IL271074A - Treatment of inflammatory diseases with inhibitors of c5a activity - Google Patents
Treatment of inflammatory diseases with inhibitors of c5a activityInfo
- Publication number
- IL271074A IL271074A IL271074A IL27107419A IL271074A IL 271074 A IL271074 A IL 271074A IL 271074 A IL271074 A IL 271074A IL 27107419 A IL27107419 A IL 27107419A IL 271074 A IL271074 A IL 271074A
- Authority
- IL
- Israel
- Prior art keywords
- inhibitors
- activity
- treatment
- inflammatory diseases
- inflammatory
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Compounds Of Unknown Constitution (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17177657 | 2017-06-23 | ||
| EP17189938 | 2017-09-07 | ||
| PCT/EP2018/065676 WO2018234118A1 (en) | 2017-06-23 | 2018-06-13 | Treatment of inflammatory diseases with inhibitors of c5a activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL271074A true IL271074A (en) | 2020-01-30 |
Family
ID=62636193
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL271074A IL271074A (en) | 2017-06-23 | 2019-12-01 | Treatment of inflammatory diseases with inhibitors of c5a activity |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP3642230A1 (en) |
| JP (1) | JP7502865B2 (en) |
| KR (1) | KR20200020727A (en) |
| CN (1) | CN111201241A (en) |
| AU (1) | AU2018286754A1 (en) |
| CA (1) | CA3066689C (en) |
| IL (1) | IL271074A (en) |
| SG (1) | SG11201912882QA (en) |
| TW (1) | TWI786132B (en) |
| WO (1) | WO2018234118A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7102353B2 (en) | 2016-06-14 | 2022-07-19 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Anti-C5 antibodies and their use |
| MA51147A (en) | 2017-12-13 | 2021-03-24 | Regeneron Pharma | ANTI-C5 ANTIBODY ASSOCIATIONS AND ASSOCIATED USES |
| JP2022524449A (en) * | 2019-03-14 | 2022-05-02 | モルフォシス・アーゲー | Antibodies targeting C5aR |
| TW202140553A (en) * | 2020-01-13 | 2021-11-01 | 美商威特拉公司 | Antibody molecules to c5ar1 and uses thereof |
| KR20230024421A (en) * | 2020-06-24 | 2023-02-20 | 스테이드슨 (베이징) 바이오팔마슈티칼스 캄퍼니 리미티드 | Antibodies that specifically recognize C5A and applications thereof |
| EP4277931A1 (en) | 2021-01-13 | 2023-11-22 | Visterra, Inc. | Humanized complement 5a receptor 1 antibodies and methods of use thereof |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4704355A (en) | 1985-03-27 | 1987-11-03 | New Horizons Diagnostics Corporation | Assay utilizing ATP encapsulated within liposome particles |
| CA2025907A1 (en) | 1989-09-21 | 1991-03-22 | Franklin D. Collins | Method of transporting compositions across the blood brain barrier |
| DE69133566T2 (en) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Formation of xenogenic antibodies |
| AUPO755097A0 (en) | 1997-06-25 | 1997-07-17 | University Of Queensland, The | Receptor agonist and antagonist |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| AUPR833401A0 (en) | 2001-10-17 | 2001-11-08 | University Of Queensland, The | G protein-coupled receptor antagonists |
| DK2860251T3 (en) | 2004-02-12 | 2018-06-06 | Archemix Llc | APTAPMER PHARMACEUTICALS USEFUL IN TREATMENT OF COMPLEMENT-RELATED DISEASES |
| SG151283A1 (en) * | 2004-03-26 | 2009-04-30 | Promics Pty Ltd | Treatment of neurological conditions using complement c5a receptor modulators |
| AU2007276707A1 (en) * | 2006-07-21 | 2008-01-24 | Promics Pty Ltd | Treatment for intimal hyperplasia and related conditions |
| GB0617734D0 (en) | 2006-09-08 | 2006-10-18 | Evolutec Ltd | Method of treating peripheral nerve disorders |
| EP3078658B1 (en) | 2008-12-22 | 2019-04-10 | ChemoCentryx, Inc. | C5ar antagonists |
| GB0905790D0 (en) * | 2009-04-03 | 2009-05-20 | Alligator Bioscience Ab | Novel polypeptides and use thereof |
| EP2327725A1 (en) | 2009-11-26 | 2011-06-01 | InflaRx GmbH | Anti-C5a binding moieties with high blocking activity |
| PL2585064T3 (en) | 2010-06-24 | 2017-09-29 | Chemocentryx, Inc. | C5ar antagonists |
| CN114015692A (en) * | 2013-03-14 | 2022-02-08 | 阿尔尼拉姆医药品有限公司 | Complement component C5 iRNA compositions and methods of use thereof |
| WO2014180961A1 (en) * | 2013-05-08 | 2014-11-13 | Novo Nordisk A/S | Use of c5ar antagonists |
| CN106132982A (en) | 2014-03-20 | 2016-11-16 | 因弗拉克斯有限责任公司 | For treating the C5a inhibitor of viral pneumonia |
| WO2016044419A1 (en) | 2014-09-16 | 2016-03-24 | Alnylam Pharmaceuticals, Inc. | Complement component c5 irna compositions and methods of use thereof |
| TR201903267T4 (en) | 2014-10-15 | 2019-03-21 | Alexion Pharma Inc | Replication methods of large-scale eculizumab production cell culture. |
| FR3030515B1 (en) * | 2014-12-23 | 2017-01-20 | Galderma Res & Dev | NOVEL ANTAGONIST COMPOUNDS FOR CHEMOKINE CXCR1 AND CXCR2 RECEPTORS AND THEIR USE IN THE TREATMENT OF CHEMOKINE MEDIATED PATHOLOGIES |
| EP3313437A1 (en) | 2015-06-26 | 2018-05-02 | Alexion Pharmaceuticals, Inc. | A method for treating a patient in compliance with vaccination with eculizumab or an eculizumab variant |
| KR102395093B1 (en) | 2016-04-04 | 2022-05-04 | 케모센트릭스, 인크. | Soluble C5aR antagonists |
| ES2893769T3 (en) * | 2017-04-03 | 2022-02-10 | Inflarx Gmbh | Treatment of inflammatory diseases with inhibitors of C5a activity |
-
2018
- 2018-06-13 KR KR1020197038211A patent/KR20200020727A/en not_active Application Discontinuation
- 2018-06-13 JP JP2019570986A patent/JP7502865B2/en active Active
- 2018-06-13 CA CA3066689A patent/CA3066689C/en active Active
- 2018-06-13 AU AU2018286754A patent/AU2018286754A1/en active Pending
- 2018-06-13 TW TW107120362A patent/TWI786132B/en active
- 2018-06-13 EP EP18732016.3A patent/EP3642230A1/en active Pending
- 2018-06-13 CN CN201880041303.4A patent/CN111201241A/en active Pending
- 2018-06-13 WO PCT/EP2018/065676 patent/WO2018234118A1/en unknown
- 2018-06-13 SG SG11201912882QA patent/SG11201912882QA/en unknown
-
2019
- 2019-12-01 IL IL271074A patent/IL271074A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TWI786132B (en) | 2022-12-11 |
| KR20200020727A (en) | 2020-02-26 |
| CN111201241A (en) | 2020-05-26 |
| AU2018286754A1 (en) | 2019-12-19 |
| EP3642230A1 (en) | 2020-04-29 |
| SG11201912882QA (en) | 2020-01-30 |
| CA3066689A1 (en) | 2018-12-27 |
| CA3066689C (en) | 2024-01-16 |
| WO2018234118A1 (en) | 2018-12-27 |
| TW201904611A (en) | 2019-02-01 |
| JP2020524696A (en) | 2020-08-20 |
| JP7502865B2 (en) | 2024-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201906485B (en) | Treatment of inflammatory diseases with inhibitors of c5a activity | |
| IL273693A (en) | Treatment of inflammatory disorders | |
| IL271074A (en) | Treatment of inflammatory diseases with inhibitors of c5a activity | |
| IL253796A0 (en) | Therapeutically active compounds and their methods of use | |
| IL251246A0 (en) | Therapeutically active compounds and their methods of use | |
| IL249223A0 (en) | Mth1 inhibitors for treatment of inflammatory and autoimmune conditions | |
| IL290980A (en) | Rna for treatment of autoimmune diseases | |
| IL264048A (en) | Pde9 inhibitors for treatment of peripheral diseases | |
| IL253118A0 (en) | Methods of treating inflammatory diseases | |
| HK1252037A1 (en) | Methods of treating inflammatory diseases | |
| EP3503903A4 (en) | Ascaroside treatment of autoimmune and inflammatory diseases | |
| HK1258762A1 (en) | Combinations of the btk inhibitor gs-4059 with inhibitors selected from a jak, ask1, brd and/or mmp9 inhibitor to treat cancer, allergic disorders, autoimmune diseases or inflammatory diseases | |
| HUE052766T2 (en) | Treatment of neurological diseases | |
| GB201412578D0 (en) | Treatment of neurological diseases | |
| EP3197474C0 (en) | Inhibitors of nf kappa-b activity for treatment of diseases and disorders | |
| GB201515244D0 (en) | Treatment of inflammatory disease or condition | |
| GB201805100D0 (en) | Treatment of sarcopenic diseases | |
| HK1243961A1 (en) | Prevention and treatment of inflammatory conditions | |
| EP4003283C0 (en) | Treatment of inflammatory skin conditions | |
| GB201706662D0 (en) | Treatment of neurological diseases | |
| GB201604253D0 (en) | Treatment of genetic diseases | |
| GB201517565D0 (en) | Treatment of genetic diseases | |
| ZA201700571B (en) | Therapeutically active compounds and their methods of use | |
| GB201514909D0 (en) | Treatment of autoimmune diseases | |
| SG10201913141UA (en) | Treatment of alphavirus-induced inflammation |